The role of c-erbB-2 expression on the survival of patients with small-cell lung cancer

The aim of this study was to determine the incidence and role of c-erbB-2 overexpression as a predictive/prognostic marker in small-cell lung carcinoma (SCLC). We performed a retrospective study on subjects with a biopsy-proven diagnosis of SCLC. A chart review for demographic and clinical data was...

Full description

Saved in:
Bibliographic Details
Published in:Lung 2006-10, Vol.184 (5), p.267-272
Main Authors: Canoz, Ozlem, Ozkan, Metin, Arsav, Vedat, Er, Ozlem, Coskun, H Senol, Soyuer, Serdar, Altinbas, Mustafa
Format: Article
Language:English
Subjects:
Adult
Aged
Biomarkers, Tumor - biosynthesis
Biopsy
Bronchoscopy
Carcinoma, Small Cell - metabolism
Carcinoma, Small Cell - mortality
Carcinoma, Small Cell - pathology
Cellular biology
Female
Gene expression
Humans
Immunohistochemistry
Lung cancer
Lung Neoplasms - metabolism
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Male
Medical prognosis
Middle Aged
Receptor, ErbB-2 - biosynthesis
Retrospective Studies
Survival Rate - trends
Turkey - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to determine the incidence and role of c-erbB-2 overexpression as a predictive/prognostic marker in small-cell lung carcinoma (SCLC). We performed a retrospective study on subjects with a biopsy-proven diagnosis of SCLC. A chart review for demographic and clinical data was performed on patients with SCLC diagnosed between 1998 and 2004. c-erbB-2 overexpression was evaluated using immunohistochemistry performed on archival paraffin-embedded specimens. Sixty-seven patients with SCLC were identified (6 females, 61 males; median age- 56.5 yr, range-34-75) all of whom had adequate tissue specimens available for c-erB-2 testing. Of the 67 specimens, 12 (17.9%) showed c-erbB-2 overexpression. Seventy-five of the cases were positive for c-erbB-2, had extensive disease. The median overall survival of patients with SCLC whose tumors were positive and negative for c-erbB-2 were 8 +/- 0.9 months (95%CI 6.3-9.7) and 11 +/- 1.5 months (95%CI 8.0-14.0), respectively. c-erbB-2 overexpression detected using immunohistochemistry is observed in 17.9% of patients with SCLC and has statistically significant prognostic value. Our findings suggest that c-erbB-2 may be a potential target for site-specific immunotherapy in SCLC. Considering one technique examined, further molecular investigation is needed to confirm these preliminary findings.
ISSN:0341-2040
1432-1750
DOI:10.1007/s00408-005-2591-y